@article{b45f3c8621d34cfbbcd5f459bcb10dc0,
title = "Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia",
abstract = "Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.",
author = "Tadeusz Robak and Anna Dmoszynska and Philippe Solal-C{\'e}ligny and Krzysztof Warzocha and Javier Loscertales and John Catalano and Afanasiev, {Boris V} and Loree Larratt and Geisler, {Christian H} and Marco Montillo and Ilya Zyuzgin and Ganly, {Peter S} and Caroline Dartigeas and Andr{\'a}s Rosta and J{\"o}rg Maurer and Myriam Mendila and Saville, {M Wayne} and Nancy Valente and Wenger, {Michael K} and Moiseev, {Sergey I}",
year = "2010",
month = apr,
day = "1",
doi = "10.1200/JCO.2009.26.4556",
language = "English",
volume = "28",
pages = "1756--65",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",
}